Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors ...

Delivered Q4 and FY2025 revenue above guidanceBest ARR performance of the year in Q4 with total ending ARR of $124 millionRecord percentage of ARR in multi-year agreements and record number of ...

Updated data for casdatifan in late-line kidney cancer demonstrated median progression-free survival (PFS) of 15.1 months and a confirmed overall response rate (cORR) of 45% for the 100mg once-daily ...

CAMBRIDGE, Mass.-- (BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the fourth quarter and ...

AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and ...

Total Revenue of $256 Million2025 Software Revenue of $200 Million; 2025 Software ACV of $198 MillionStrong Balance Sheet Supports Path to Positive Adjusted EBITDA by Year-End 2028Accelerating ...

Fourth Quarter and Full Year 2025 Revenue and Adjusted EBITDA Results In-line with Previous GuidancePharma Direct Revenue Beats Previous Outlook with Over 40% Year-Over-Year Growth for 2025SANTA ...

Conference Call and Webcast Scheduled for Thursday, March 5, 2026 at 4:30 PMWESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an ...

Durable royalties portfolio generated $58.4 million in revenue for the fourth quarter and $250.3 million for the full yearIST achieved U.S. net product sales of $33.9 million for the fourth quarter ...

March 10 product launch event offers practical AI, digital care, and medical-grade computing innovationsLAS VEGAS--(BUSINESS WIRE)--#HIMMS26--HIMSS 2026 -- Taiwan Excellence will make its first-ever ...

NDA for rusfertide submitted to the US Food and Drug Administration (FDA), with potential approval and launch this yearCompany expects to opt-out of the 50:50 profit and loss sharing arrangement for ...

Leveragen, Inc., a Boston-based biotechnology company advancing next-generation in vivo antibody discovery, announced today ...